General Information (Tables)

3 Months Ended

Mar. 31, 2013

Business Combinations [Abstract]

Schedule Of Purchase Price Allocation

Purchase price allocation

Cash	$	357,276
Inventories		13,843
Other receivables		306,731
Intangibles		30,111,909
Fixed assets		418,483
Accounts payable and accrued liabilities		(1,893,833	)
Grants received		(1,677,348	)
Short term loans to related parties		(154,631	)
Bridge loan		(2,334,326	)
Other liabilities		(73,483	)
Total purchase price		25,074,621

Schedule Of Unaudited pro forma operation results

Unaudited pro forma operation results for the year ended December 31, 2012 as though the Company acquired Genetic Immunity on January 1, 2012 are set forth below:

Net Sales	$	—
Cost of Sales		—
Gross margin		—
Material expenses		68,406
General administration		1,482,366
Research and development		—
Personnel expenses		724,264
Depreciation and amortization		191,427
Grants received		(518,631	)
Other expenses, net		347,448
Operating expenses		2,295,280
Loss from operations		(2,295,280	)
Interest income and exchange gains		(279,982	)
Loss before income taxes		(2,575,262	)
Income taxes		(1,985	)
Net loss		(2,577,247	)